{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T17:39:39Z","timestamp":1789061979510,"version":"build-2803163510"},"reference-count":23,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.clinthera.2024.08.016","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T11:14:27Z","timestamp":1726485267000},"page":"877-882","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia"],"prefix":"10.1016","volume":"46","author":[{"given":"Jing","family":"Nie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huina","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.08.016_bib0001","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/CM9.0000000000001811","article-title":"Chronic lymphocytic leukemia in China","volume":"135","author":"Gale","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0002","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1182\/blood-2010-05-285221","article-title":"The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect","volume":"116","author":"Wu","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0003","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41375-020-01057-5","article-title":"Ethnic and geographic diversity of chronic lymphocytic leukaemia","volume":"35","author":"Yang","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0004","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood.2020004922","article-title":"Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0005","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s40265-019-01252-4","article-title":"Zanubrutinib: first approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0006","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0007","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0272989X20978958","article-title":"Extrapolation of survival curves using standard parametric models and flexible parametric spline models: comparisons in large registry cohorts with advanced cancer","volume":"41","author":"Gray","year":"2021","journal-title":"Med Decis Making"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0008","unstructured":"National Bureau of Statistics. Birth rate, mortality rate and natural growth rate. 2023. https:\/\/data.stats.gov.cn\/easyquery.htm?cn=C01&zb=A0302&sj=2023. Accessed [2024-01-02]."},{"key":"10.1016\/j.clinthera.2024.08.016_bib0009","series-title":"China Guidelines for Pharmacoeconomic Evaluations","author":"Guoen","year":"2020"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0010","unstructured":"National Bureau of Statistics. Statistical bulletin of the people\u2019s Republic of China on national economic and social development in 2021. 2023. https:\/\/www.gov.cn\/xinwen\/2022-02\/28\/content_5676015.htm. Accessed [2024-01-02]."},{"key":"10.1016\/j.clinthera.2024.08.016_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.830380","article-title":"Cost-effectiveness of tislelizumab versus docetaxel for previously treated advanced non-small-cell lung cancer in China","volume":"13","author":"Gong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0012","series-title":"Report on the Nutrition and Chronic Diseases Status of Chinese Residents. Beijing: People's Medical Publishing House","year":"2020"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0013","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40273-013-0125-7","article-title":"Modelling the cost effectiveness of rituximab in chronic lymphocytic leukaemia in first-line therapy and following relapse","volume":"32","author":"Adena","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0014","unstructured":"Shandong drug centralized procurement platforms. 2023. http:\/\/117.73.254.238:9000\/yptrade\/index.html. Accessed [2023-07-07]."},{"key":"10.1016\/j.clinthera.2024.08.016_bib0015","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.jval.2022.04.001","article-title":"Cost-effectiveness and economic burden analyses on all first-line treatments of chronic lymphocytic leukemia","volume":"25","author":"Alrawashdh","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2016.02.005","article-title":"Cost-effectiveness of first-line chronic lymphocytic leukemia treatments when full-dose fludarabine is unsuitable","volume":"38","author":"Soini","year":"2016","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0017","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/17474086.2022.2061456","article-title":"Cost-effectiveness analysis of azacitidine maintenance therapy in patients with acute myeloid leukemia","volume":"15","author":"Zhu","year":"2022","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0018","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1001\/jamaoncol.2018.7086","article-title":"First-line nivolumab plus ipilimumab vs sunitinib for metastatic renal cell carcinoma: a cost-effectiveness analysis","volume":"5","author":"Wan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0019","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/cncr.31931","article-title":"Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0020","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0021","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/bloodadvances.2017015461","article-title":"Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p","volume":"2","author":"Barnes","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0022","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.08.016_bib0023","doi-asserted-by":"crossref","first-page":"e18856","DOI":"10.1200\/JCO.2021.39.15_suppl.e18856","article-title":"Cost-effectiveness of zanubrutinib versus ibrutinib in adult patients with Waldenstr\u00f6m macroglobulinemia in the United States","volume":"39","author":"Castillo","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T01:03:10Z","timestamp":1732410190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0149291824002418"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.016","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness of Zanubrutinib Versus Bendamustine and Rituximab in Patients With Untreated Chronic Lymphocytic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}